Alpine Immune Sciences, Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating Alpine (Nasdaq: ALPN) for possible breaches of fiduciary duty and other violations of law in its transaction with Vertex.

In the transaction, Alpine stockholders will own only $65 per share or approximately $4.9 billion in cash. The transaction agreement unreasonably limits competing transactions for Alpine by imposing a significant penalty if Alpine accepts a competing bid. Alpine insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Alpine’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.